Innate Pharma SA Cash And Cash Equivalents
Innate Pharma SA (IPHYF) had Cash And Cash Equivalents of EUR 28.09 million as of 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Notes
ifrs-full:CashAndCashEquivalents · last filed 2026-04-01
- 2025-12-31: Cash And Cash Equivalents 28.09M EUR.
- 2025-06-30: Cash And Cash Equivalents 53.70M EUR.
- 2024-12-31: Cash And Cash Equivalents 66.40M EUR.
- 2024-06-30: Cash And Cash Equivalents 69.99M EUR; Cash And Cash Equivalents as first filed 69.99M EUR.
| Period end | Cash And Cash Equivalents | Cash And Cash Equivalents as first filed |
|---|---|---|
| 2025-12-31 | 28.09M EUR 20-F · filed 2026-04-01 | |
| 2025-06-30 | 53.70M EUR 6-K · filed 2025-09-17 | |
| 2024-12-31 | 66.40M EUR 20-F · filed 2026-04-01 | |
| 2024-06-30 | 69.99M EUR 6-K · filed 2025-09-17 | 69.99M EUR 6-K · filed 2024-09-12 |
| 2023-12-31 | 70.61M EUR 20-F · filed 2026-04-01 | |
| 2023-06-30 | 71.41M EUR 6-K · filed 2024-09-12 | |
| 2022-12-31 | 84.22M EUR 20-F · filed 2026-04-01 | |
| 2022-06-30 | 102.95M EUR 6-K · filed 2023-09-14 | |
| 2021-12-31 | 103.76M EUR 20-F · filed 2025-04-30 | |
| 2021-06-30 | 103.98M EUR 6-K · filed 2022-09-15 | |
| 2020-12-31 | 136.79M EUR 20-F · filed 2024-04-04 | |
| 2020-06-30 | 131.54M EUR 6-K · filed 2021-09-15 | |
| 2019-12-31 | 202.89M EUR 20-F · filed 2023-04-06 | |
| 2018-12-31 | 152.31M EUR 20-F · filed 2022-04-04 | |
| 2017-12-31 | 99.37M EUR 20-F · filed 2021-04-27 | |
| 2016-12-31 | 175.91M EUR 20-F · filed 2020-04-24 |